Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human LRP6 Anticorps:
anti-Mouse (Murine) LRP6 Anticorps:
anti-Rat (Rattus) LRP6 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal LRP6 Primary Antibody pour IHC (p), WB - ABIN390100
Brown, Twells, Hey, Cox, Levy, Soderman, Metzker, Caskey, Todd, Hess: Isolation and characterization of LRP6, a novel member of the low density lipoprotein receptor gene family. dans Biochemical and biophysical research communications 1998
Show all 4 Pubmed References
Human Polyclonal LRP6 Primary Antibody pour CyTOF, FACS - ABIN4899465
Gustafson, Smith: Activation of canonical wingless-type MMTV integration site family (Wnt) signaling in mature adipocytes increases beta-catenin levels and leads to cell dedifferentiation and insulin resistance. dans The Journal of biological chemistry 2010
Show all 3 Pubmed References
Human Polyclonal LRP6 Primary Antibody pour IF (cc), IF (p) - ABIN743558
Chen, Xu, Ye, Li, Gong, Zhang, Wu, Jia, Liu, Chen, Yang, Tang, Zhu, Ge, Zou: Urotensin II inhibited the proliferation of cardiac side population cells in mice during pressure overload by JNK-LRP6 signalling. dans Journal of cellular and molecular medicine 2014
Show all 2 Pubmed References
Human Monoclonal LRP6 Primary Antibody pour CyTOF, FACS - ABIN4899464
Madan, Walker, Young, Quick, Orgel, Ryan, Gupta, Henrich, Ferrer, Marine, Roberts, Arthur, Berndt, Oliveira, Moon, Virshup, Chou, Major: USP6 oncogene promotes Wnt signaling by deubiquitylating Frizzleds. dans Proceedings of the National Academy of Sciences of the United States of America 2016
Show all 2 Pubmed References
Human Polyclonal LRP6 Primary Antibody pour IHC (p), IHC - ABIN250317
Liu, Mani, Davis, Sarrafzadegan, Kavathas, Mani: Mutation in EGFP domain of LDL receptor-related protein 6 impairs cellular LDL clearance. dans Circulation research 2008
Show all 2 Pubmed References
Human Polyclonal LRP6 Primary Antibody pour ELISA, IHC - ABIN6263009
Zhu, Wang, Zhao, Zhang, Wu, Wang, Hu: Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma. dans Oncotarget 2017
Human Polyclonal LRP6 Primary Antibody pour ELISA, WB - ABIN6271854
Du, Wang, Ye, He, Li, Du, Liu, Zhu: Exercise training ameliorates bleomycin-induced epithelial mesenchymal transition and lung fibrosis through restoration of H2 S synthesis. dans Acta physiologica (Oxford, England) 2018
Lrp6 asymmetry is controlled by Wnt (Montrer WNT2 Anticorps)/PCP (Montrer PRCP Anticorps) signaling, indicating that this pathway regulates not only planar- but also apicobasal cell polarity.
PTK7 (Montrer PTK7 Anticorps) and LRP6 proteins physically interact, suggesting that PTK7 (Montrer PTK7 Anticorps) stabilization of LRP6 protein reciprocally regulates both canonical and noncanonical Wnt (Montrer WNT2 Anticorps) activities in the embryo.
Results suggest that Rap2 (Montrer RAP2A Anticorps) acts via TNIK (Montrer TNIK Anticorps) to regulate the stability of LRP6 receptor for Wnt (Montrer WNT2 Anticorps) signaling.
The extracellular domains of Lrp5 (Montrer LRP5 Anticorps)/6 behave as physiologically relevant inhibitors of noncanonical Wnt (Montrer WNT2 Anticorps) signaling during Xenopus and mouse development in vivo.
Lrp6 plays a critical role in the switch from Wnt (Montrer WNT2 Anticorps)/PCP (Montrer PRCP Anticorps) to Wnt (Montrer WNT2 Anticorps)/beta-catenin (Montrer CTNNB1 Anticorps) signaling.
Kremen2 (Montrer KREMEN2 Anticorps) knockdown specifically reduces LRP6 protein levels in neural crest explants.
Waif1a binds to the Wnt (Montrer WNT2 Anticorps) coreceptor LRP6 (Montrer LRP5 Anticorps) and inhibits Wnt (Montrer WNT2 Anticorps)-induced LRP6 (Montrer LRP5 Anticorps) internalization into endocytic vesicles, a process that is required for pathway activation.
Results identify GRK5 (Montrer GRK5 Anticorps)/6 as novel kinases for the single transmembrane receptor LRP6 (Montrer LRP5 Anticorps) during Wnt (Montrer WNT2 Anticorps) signaling.
Three rare missense mutations (c.1514A>G, p.Y505C); c.2984A>G, p.D995G; and c.4280C>A, p.P1427Q) of the LRP6 gene were identified in Chinese NTD patients. The Y505C mutation is a loss-of-function mutation on both WNT (Montrer WNT2 Anticorps)/beta-catenin (Montrer CTNNB1 Anticorps) and PCP (Montrer PRCP Anticorps) signaling. The D995G mutation partially lost inhibition on PCP (Montrer PRCP Anticorps) signaling without affecting WNT (Montrer WNT2 Anticorps)/beta-catenin (Montrer CTNNB1 Anticorps) signaling. The P1427Q mutation dramatically increased WNT (Montrer WNT2 Anticorps)/beta-catenin (Montrer CTNNB1 Anticorps) signa...
LRP6 endocytosis proceeds by two routes, depending on the presence of LDL, and that LRP6 controls the intracellular destination of NPC1L1 (Montrer NPC1L1 Anticorps) in hepatocytes.
High Expressions of LRP6 is associated with cancer.
LRP6 expression was found to be upregulated in oral squamous cell carcinoma tissues, and correlated with a cluster of clinicopathologic parameters, including smoking, drinking, tumor differentiation status, lymph node metastasis and survival time.
CCN2 (Montrer CTGF Anticorps) plays a promoting role in hepatocellular carcinoma (HCC (Montrer FAM126A Anticorps))progression through activating LRP6 in a HSPGs-dependent manner. Heparin in combination with chemotherapy has a synergic effect and could be a treatment choice for HCCs (Montrer HCCS Anticorps) with a high CCN2 (Montrer CTGF Anticorps) expression.
Increased LRP6 gene expression is associated with colorectal cancer.
Therefore, our study demonstrates that miR (Montrer MLXIP Anticorps)-183 is a tumor suppressor microRNA that plays a major role in OS.
data suggest that LRP6 promotes negative breast cancer cell migration and invasion by regulating the expression and function of S100A4 (Montrer S100A4 Anticorps) via the Wnt (Montrer WNT2 Anticorps)/beta-catenin (Montrer CTNNB1 Anticorps) signaling pathway
sustained activation of Wnt (Montrer WNT2 Anticorps)/beta-catenin (Montrer CTNNB1 Anticorps) signaling due to abrogation of Merlin (Montrer NF2 Anticorps)-mediated inhibition of LRP6 phosphorylation may be a cause of Neurofibromatosis type II disease.
LRP6 ectodomain becomes highly compact upon complexation with the Wnt (Montrer WNT2 Anticorps) antagonist Dkk1 (Montrer DKK1 Anticorps), suggesting a potential role for the ectodomain conformational change in the regulation of receptor oligomerization and signaling.
LRP6 acts as a scaffold protein (Montrer HOMER1 Anticorps) in cardiac gap junction assembly and intracellular protein (Montrer CKAP2 Anticorps) trafficking.
Data show that reduction of alpha chain (Montrer FCGRT Anticorps) of nascent polypeptide associated complex (Montrer NACa1 Anticorps) (alphaNAC) levels decreased basal expression of Low density lipoprotein receptor-Related Protein 6 (Lrp6) by 30%.
GPR37 is required for Wnt/beta-catenin signaling and protects LRP6 from ER-associated degradation via CHIP (carboxyl terminus of Hsc70-interacting protein) and the ATPase VCP
Lrp6 is the key mediator of Wnt3a (Montrer WNT3A Anticorps) signaling in osteoblasts and Lrp5 (Montrer LRP5 Anticorps) played a less significant role in mediating Wnt3a (Montrer WNT3A Anticorps) signaling.
VAP1 (Montrer AOC3 Anticorps) cleaved recombinant mouse LRP6, producing a 140-kDa fragment. An antibody against a peptide including the LRP6-cleavage site inhibited VAP1 (Montrer AOC3 Anticorps)-induced VE-cadherin (Montrer CDH5 Anticorps) relocation and disruption of cell-cell adhesions and blocked haemorrhage in mice in vivo.
we identified Lrp6, the gene encoding the coreceptor to Frizzled in the Wnt (Montrer WNT2 Anticorps) pathway, as a potential negative regulator of precursor proliferation. Overexpression and siRNA silencing confirmed the regulatory role of Lrp6
These results revealed a new role of the canonical Lrp5 (Montrer LRP5 Anticorps)/6-beta-catenin (Montrer CTNNB1 Anticorps) pathway in regulating the morphogenesis of the cerebellum during postnatal development.
Data (including data from studies in knockout/transgenic mice) suggest Lrp6 is required for suppression of Sost (sclerostin (Montrer SOST Anticorps)) expression by parathyroid hormone (Montrer PTH Anticorps) (here, human PTH (Montrer PTH Anticorps) peptide 1-34); LRP6 regulates osteocytes expression of histone deacetylases.
Lrp5 (Montrer LRP5 Anticorps) binds to Frizzled, preventing Frz-regulated non-canonical Wnt (Montrer WNT2 Anticorps) pathway activation and further non-canonical pathway-mediated tumour metastasis.
Wt1 (Montrer WT1 Anticorps) expression levels in podocytes regulate Wnt (Montrer WNT2 Anticorps)/beta-catenin (Montrer CTNNB1 Anticorps) signaling through modulating the endocytic fate of LRP6, and this indicates a potential target for the therapy of CKD.
This gene encodes a member of the low density lipoprotein (LDL) receptor gene family. LDL receptors are transmembrane cell surface proteins involved in receptor-mediated endocytosis of lipoprotein and protein ligands. The protein encoded by this gene functions as a receptor or, with Frizzled, a co-receptor for Wnt and thereby transmits the canonical Wnt/beta-catenin signaling cascade. Through its interaction with the Wnt/beta-catenin signaling cascade this gene plays a role in the regulation of cell differentiation, proliferation, and migration and the development of many cancer types. This protein undergoes gamma-secretase dependent RIP- (regulated intramembrane proteolysis) processing but the precise locations of the cleavage sites have not been determined.
low density lipoprotein receptor-related protein 6
, lipoprotein receptor-related protein 6
, low-density lipoprotein receptor-related protein 6
, low-density lipoprotein receptor-related protein 6-like
, low density lipoprotein receptor-related protein 6; low density lipoprotein-related protein 6
, low density lipoprotein-related protein 6